Trial Profile
Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Epilepsy
- Focus Pharmacodynamics
- Sponsors Sunovion Pharmaceuticals
- 27 Apr 2018 Results of analysis evaluating accuracy and utility of automated kit assay for detection of thyroid hormone level presented at the 70th Annual Meeting of the American Academy of Neurology
- 05 Dec 2017 Results presented at the 71st Annual Meeting of the American Epilepsy Society
- 29 Nov 2017 According to a Sunovion Pharmaceuticals media release, data of the trial will be presented at the American Epilepsy Society (AES) Annual Meeting 2017.